Nasdaq: VTRSViatris

    Viatris completes $1.69 billion Pacira BioSciences acquisition

    • US stocks
    • Mergers & acquisitions
    • Health Care
    A glass thermometer lying across a pile of white tablets, orange and yellow capsules, and green-and-white capsules
    Steve Buissinne (stevepb), via Wikimedia Commons (CC0). Illustrative image.

    Viatris (Nasdaq: VTRS) completed its acquisition of Pacira BioSciences, it said on 17 Nov 2026. The aggregate amount paid by its subsidiary in the tender offer and merger is approximately $1.69 billion, excluding related fees and expenses. Pacira shares were acquired for $36.50 each in cash and will be delisted from the Nasdaq Global Select Market.

    Key highlights

    • Price per Pacira share: $36.50 in cash
    • Aggregate amount paid: $1.69 billion, excluding related fees and expenses
    • Shares validly tendered: 32,929,780, about 66.46% of shares outstanding at the Expiration Time
    • Expected Pacira revenue, 17 Nov to 31 Dec 2026: $90.0 million to $100.0 million
    • Completion date: 17 Nov 2026

    The deal in numbers

    ItemDetail
    AcquirerViatris Inc. through Peach Purchaser Sub Inc., a wholly owned subsidiary
    TargetPacira BioSciences, Inc.
    Price per share$36.50 per share in cash, net of applicable withholding taxes, without interest
    Tender offer expiryOne minute after 11:59 p.m. Eastern Time, 16 Nov 2026
    Shares validly tenderedAbout 32,929,780, or approximately 66.46% of shares outstanding
    Aggregate amount paidApproximately $1.69 billion, excluding related fees and expenses
    FundingCash on hand and short-term borrowings
    Merger completed17 Nov 2026, under Section 251(h) of the Delaware General Corporation Law, without a Pacira stockholder vote

    Pacira becomes a wholly owned subsidiary

    Viatris announced the merger agreement with Pacira on 8 Oct 2026. Its subsidiary began the tender offer on 30 Oct 2026 at $36.50 per share in cash. The offer expired on 16 Nov 2026, and the company said that about 66.46% of outstanding shares had been validly tendered.

    On 17 Nov 2026 the subsidiary accepted the tendered shares for payment and merged with Pacira. Pacira continues as the surviving corporation and a wholly owned subsidiary of Viatris. Shares not tendered were converted into the right to receive the same $36.50 per share in cash.

    Viatris says Pacira will be delisted from the Nasdaq Global Select Market as part of the completion.

    Revenue outlook and stated purpose

    Viatris expects the acquisition to contribute total revenues of between $90.0 million and $100.0 million for the period from 17 Nov 2026 through 31 Dec 2026, a figure the company gives as its own expectation.

    Chief executive Scott A. Smith said the deal strengthens the company's U.S. innovative medicines business and brings together complementary portfolios and capabilities in non-opioid pain management. Pacira is described in the release as a leader in non-opioid pain management.

    What the Pacira deal means for Viatris shareholders

    The filing does not give the total number of Pacira shares outstanding, the premium to prior trading prices, the split between cash on hand and short-term borrowings, or any effect of the acquisition on Viatris's reported earnings beyond the expected revenue range. It also does not give Pacira's revenue or earnings for earlier periods.

    The merger is complete, so no further stockholder vote on it was required, and the Merger Agreement was filed with the 8 Oct 2026 8-K with schedules omitted.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Related posts

    All Viatris articles